FDA Approves Degarelix to Treat Advanced Prostate Cancer

Article

Ferring Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer.

Ferring Pharmaceuticals received approval from the US Food and Drug Administration (FDA) for degarelix, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for patients with advanced prostate cancer. The drug will become available immediately after issuance of a trade name, which is currently under FDA review.

In phase III studies, degarelix was at least as effective as leuprolide (Lupron Depot) in sustaining castrate levels of testosterone, and significantly faster in reducing testosterone. At day 3 of treatment, 96% of degarelix patients achieved castrate levels of testosterone, compared with 0% on leuprolide. By day 14, 99% of degarelix patients achieved castrate levels, compared with 18% receiving leuprolide.

Degarelix is the only GnRH receptor antagonist approved by the FDA for the treatment of hormonally sensitive advanced prostate cancer.

 

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.